PortalPublikationenPrimary Vitreoretinal Lymphoma Therapy Monitoring: Significa...

Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab

Standard

Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab. / Kakkassery, Vinodh; Heindl, Ludwig M; Rokohl, Alexander C; Chronopoulos, Arygrios; Schutz, James S; Ranjbar, Mahdy; Schargus, Marc; Böker, Alexander; Winterhalter, Sibylle; Stübiger, Nicole.

in: NEUROSIGNALS, Jahrgang 29, Nr. S1, 05.05.2021, S. 1-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kakkassery, V, Heindl, LM, Rokohl, AC, Chronopoulos, A, Schutz, JS, Ranjbar, M, Schargus, M, Böker, A, Winterhalter, S & Stübiger, N 2021, 'Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab', NEUROSIGNALS, Jg. 29, Nr. S1, S. 1-7. https://doi.org/10.33594/000000367

APA

Kakkassery, V., Heindl, L. M., Rokohl, A. C., Chronopoulos, A., Schutz, J. S., Ranjbar, M., Schargus, M., Böker, A., Winterhalter, S., & Stübiger, N. (2021). Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab. NEUROSIGNALS, 29(S1), 1-7. https://doi.org/10.33594/000000367

Vancouver

Kakkassery V, Heindl LM, Rokohl AC, Chronopoulos A, Schutz JS, Ranjbar M et al. Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab. NEUROSIGNALS. 2021 Mai 5;29(S1):1-7. https://doi.org/10.33594/000000367

Bibtex

@article{a4bba9988bdf4ce69b47d7eb48959e10,
title = "Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab",
abstract = "BACKGROUND/AIMS: Intravitreal rituximab is an off-label treatment option for primary vitreoretinal lymphoma (PVRL). The objective of this study was to monitor the therapeutic response and safety profile of intravitreal rituximab in a cohort of PVRL patients.METHODS: In this retrospective, uncontrolled, open label, multicentre study, 20 eyes from 15 consecutive patients diagnosed with PRVL received at least one intravitreal injection of 1mg in 0.1ml rituximab. Biodata of the PVRL patients was recorded as well as visual acuity and vitreous haze score immediately before rituximab intravitreal injection and at follow-up examinations. Intravitreal rituximab safety data was also recorded. Additional rituximab injections were made during control visits on a pro re nata (PRN) regime using increased vitreous haze to indicate recurrence.RESULTS: There was significant vitreous haze reduction (p=0.0002) followed by significant improvement of visual acuity (mean best visual acuity before therapy 0.57 logMAR, after therapy 0.20 logMAR (p=0.0228) during the follow-up time up to 4 years. Only mild ocular side effects were reported. Median follow-up time was 565 days (range, 7-1253 days).CONCLUSION: Intravitreal rituximab therapy shows promising PVRL regression without any severe side effects. Although our clinical data support rituximab as intravitreal therapy in PVRL disease, further study is warranted.",
keywords = "Humans, Intraocular Lymphoma, Neoplasm Recurrence, Local, Retinal Neoplasms/diagnosis, Retrospective Studies, Rituximab/therapeutic use, Vitreous Body",
author = "Vinodh Kakkassery and Heindl, {Ludwig M} and Rokohl, {Alexander C} and Arygrios Chronopoulos and Schutz, {James S} and Mahdy Ranjbar and Marc Schargus and Alexander B{\"o}ker and Sibylle Winterhalter and Nicole St{\"u}biger",
note = "{\textcopyright} Copyright by the Author(s). Published by Cell Physiol Biochem Press.",
year = "2021",
month = may,
day = "5",
doi = "10.33594/000000367",
language = "English",
volume = "29",
pages = "1--7",
journal = "NEUROSIGNALS",
issn = "1424-862X",
publisher = "S. Karger AG",
number = "S1",

}

RIS

TY - JOUR

T1 - Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab

AU - Kakkassery, Vinodh

AU - Heindl, Ludwig M

AU - Rokohl, Alexander C

AU - Chronopoulos, Arygrios

AU - Schutz, James S

AU - Ranjbar, Mahdy

AU - Schargus, Marc

AU - Böker, Alexander

AU - Winterhalter, Sibylle

AU - Stübiger, Nicole

N1 - © Copyright by the Author(s). Published by Cell Physiol Biochem Press.

PY - 2021/5/5

Y1 - 2021/5/5

N2 - BACKGROUND/AIMS: Intravitreal rituximab is an off-label treatment option for primary vitreoretinal lymphoma (PVRL). The objective of this study was to monitor the therapeutic response and safety profile of intravitreal rituximab in a cohort of PVRL patients.METHODS: In this retrospective, uncontrolled, open label, multicentre study, 20 eyes from 15 consecutive patients diagnosed with PRVL received at least one intravitreal injection of 1mg in 0.1ml rituximab. Biodata of the PVRL patients was recorded as well as visual acuity and vitreous haze score immediately before rituximab intravitreal injection and at follow-up examinations. Intravitreal rituximab safety data was also recorded. Additional rituximab injections were made during control visits on a pro re nata (PRN) regime using increased vitreous haze to indicate recurrence.RESULTS: There was significant vitreous haze reduction (p=0.0002) followed by significant improvement of visual acuity (mean best visual acuity before therapy 0.57 logMAR, after therapy 0.20 logMAR (p=0.0228) during the follow-up time up to 4 years. Only mild ocular side effects were reported. Median follow-up time was 565 days (range, 7-1253 days).CONCLUSION: Intravitreal rituximab therapy shows promising PVRL regression without any severe side effects. Although our clinical data support rituximab as intravitreal therapy in PVRL disease, further study is warranted.

AB - BACKGROUND/AIMS: Intravitreal rituximab is an off-label treatment option for primary vitreoretinal lymphoma (PVRL). The objective of this study was to monitor the therapeutic response and safety profile of intravitreal rituximab in a cohort of PVRL patients.METHODS: In this retrospective, uncontrolled, open label, multicentre study, 20 eyes from 15 consecutive patients diagnosed with PRVL received at least one intravitreal injection of 1mg in 0.1ml rituximab. Biodata of the PVRL patients was recorded as well as visual acuity and vitreous haze score immediately before rituximab intravitreal injection and at follow-up examinations. Intravitreal rituximab safety data was also recorded. Additional rituximab injections were made during control visits on a pro re nata (PRN) regime using increased vitreous haze to indicate recurrence.RESULTS: There was significant vitreous haze reduction (p=0.0002) followed by significant improvement of visual acuity (mean best visual acuity before therapy 0.57 logMAR, after therapy 0.20 logMAR (p=0.0228) during the follow-up time up to 4 years. Only mild ocular side effects were reported. Median follow-up time was 565 days (range, 7-1253 days).CONCLUSION: Intravitreal rituximab therapy shows promising PVRL regression without any severe side effects. Although our clinical data support rituximab as intravitreal therapy in PVRL disease, further study is warranted.

KW - Humans

KW - Intraocular Lymphoma

KW - Neoplasm Recurrence, Local

KW - Retinal Neoplasms/diagnosis

KW - Retrospective Studies

KW - Rituximab/therapeutic use

KW - Vitreous Body

U2 - 10.33594/000000367

DO - 10.33594/000000367

M3 - SCORING: Journal article

C2 - 33945240

VL - 29

SP - 1

EP - 7

JO - NEUROSIGNALS

JF - NEUROSIGNALS

SN - 1424-862X

IS - S1

ER -